BEN — Franklin Resources, Inc.

The market has already paid for the turnaround but won't pay more. As of 2026-09-13, BEN was +39.45% over six months yet only +0.18% over one month and -3.11% over the past week, with RSI at 46.9 and price 1.47% below its 20-day and 0.34% below its 50-day SMA. The fundamentals news has been good — record $1.79T AUM in June, $1.83T in August, $18.4B of long-term net inflows, Q3-FY26 adjusted EPS of $0.72 beating $0.66, revenue +14.3% YoY, a $1.5B CFO launch and the Stoneshield real-assets deal — but the Street's consensus is "Hold" (6 buys / 16 holds / 5 sells) with an average target of $34.60, barely above the current price. Sentiment is neither fearful nor euphoric; it's "prove it at these levels."

Revenue has ground steadily higher for three years: $1.99B in the Sep-2023 quarter to a record $2.36B in the Jun-2026 quarter (TTM ~$9.32B), with the latest quarter +14.3% YoY — the strongest YoY print in the dataset. Sequentially, the last four quarters read $2.34B → $2.33B → $2.29B → $2.36B, so this is flat-to-up progress, not a steep ramp; the YoY comparison is flattered by a soft Jun-2025 base ($2.06B). GAAP operating income is noisy but the direction off the trough is clear: -$151M in Sep-2024, then $85M (3.6% margin) in Sep-2025, $281M (12.1%), $323M (14.1%) and $216M (9.2%) in Jun-2026 — better than the 7.5% margin of a year earlier but still below the 10.5% of Jun-2024. GAAP diluted EPS of $0.31 in Jun-2026 masks a $0.72 adjusted figure; the gap is largely the $100M regulatory settlement. The real blemish is cash conversion: TTM free cash flow fell to $214M from $1,452M a year earlier, but the quarterly series (-$255M, -$40M, +$562M) shows lumpiness from consolidated investment products and seed capital rather than a steady bleed. Verdict: revenue inflecting up, margins recovering off a FY2025 trough, cash flow noisy — not a structural decline, but not yet a clean compounding story either.

Mixed-to-rich. As of 2026-09-13, the $33.65 price is 22.4x TTM EPS of $1.73 — roughly a 40% premium to BEN's own five-year average P/E of 16.04x — and 1.88x TTM sales versus a five-year average of 1.42x; both say "rich vs. its own history," which is exactly what the deterministic model flags. But that trailing EPS base is suppressed by one-off charges and regulatory costs. On Q3-FY26 adjusted EPS of $0.72 annualized (~$2.60–$2.90) and the Street's next-FY estimate of $2.892, the shares change hands at roughly 12–13x forward adjusted earnings — fair to modestly cheap for an asset manager with a 3.95% dividend yield and improving flows. P/B of 1.48x and PEG of 0.12 are not useful signals here (the PEG is a data artifact). Bottom line: not expensive on normalized earnings, but the deep-value window from the 2023–24 lows is closed.

The stock is no longer pricing in a turnaround — it is pricing in delivery. At $33.65 the market pays about 11.6x the Street's FY2027 EPS estimate of $2.892, while the average analyst target is $34.60 (high $36, low $34), i.e., essentially zero expected multiple expansion from here. That means future returns must come from earnings, not re-rating: if FY2027 lands near $2.89 and the multiple holds 12–13x, the math points to the mid-$30s and little more; if the "one-off" regulatory and integration charges keep recurring and normalized EPS is $2.30–$2.50, then $33.65 is 13–15x and no longer cheap. The set-up is a show-me on earnings quality — the $100M settlement charge normalizing and FCF inflecting back toward the $1.0B+ level — not a growth stock priced for perfection. Buy the print, not the narrative.

As of 2026-09-13, RSI(14) was 46.9 — dead neutral, neither overbought nor oversold despite the +39.45% six-month move. Price sat 1.47% below the 20-day SMA and 0.34% below the 50-day, but 16.9% above the 200-day: an intact long-term uptrend going through a short-term consolidation after -3.11% over the past week and +0.18% over the month. The stock is roughly 83% of the way up its 52-week range of $21.11–$36.28. Entry implication: no urgency to chase at $33.65; the risk/reward improves on a pullback toward the 200-day (high-$20s), while a reclaim of the 20/50-day would signal the pause is over.

• Interest rates: the 10-year Treasury near ~4.8% supports cash-management yields and structured-credit demand, but pressures fixed-income valuations, raises the discount rate applied to asset-manager multiples, and can shift client allocations away from long-duration strategies.
• Structural fee compression and the active-to-passive shift: firm-wide average fees are roughly 38bps and traditional mutual fund vehicles remain under pressure, a secular headwind that no cyclical upturn fixes.
• Private markets tailwind: alternative strategies carry ~65bps versus ~38bps firm-wide, so the Lexington/Benefit Street/Clarion build-out (now including the September 2026 Stoneshield real-assets deal) is the primary lever on margins and on the multiple.
• Regulatory and compliance scrutiny: the $100M settlement in fiscal Q3 2026 and continuing Western Asset Management attention keep compliance costs elevated and create headline risk.
• Market-level dependence: with a beta of 1.571, BEN's AUM, fee revenue and share price are all levered to the same equity and credit market direction — a drawdown hits flows and earnings simultaneously.

• Fiscal Q4/FY2026 results expected early-to-mid November 2026 — watch FY2027 margin guidance (previously framed around 29–30% for private markets) and whether the ~$40B FY2026 private-markets fundraising target was met.
• Monthly AUM and flow prints: August 2026 hit $1.83T with $8B of long-term net inflows; a continued inflow streak would confirm the organic-growth story that justifies the current multiple.
• Scaling of the Stoneshield Capital platform within Clarion Partners and deployment of the $1.5B collateralized fund obligation vehicle closed in August 2026.
• Continued capital return: $348.1M of buybacks (10.4M shares) plus $173M of dividends in Q3-FY26, with the ~3.95% yield as a floor for total return.
• Any evidence that the $100M regulatory charge is genuinely non-recurring — a clean GAAP quarter would sharply re-rate the trailing P/E optics.

• Earnings quality and cash conversion: TTM free cash flow fell to ~$214M from ~$1,452M a year earlier, and GAAP operating margin is just 9.7% against a 67.6% gross margin — if FCF does not recover toward $1B+, the dividend and buyback are being funded by balance sheet, not earnings.
• Recurring 'one-off' charges: the $100M regulatory settlement in fiscal Q3 2026 plus ongoing Western Asset compliance costs; if these repeat, adjusted EPS of $2.89 is a mirage.
• Valuation and crowding: 22.4x trailing versus a 16.0x five-year average, 1.88x sales versus 1.42x, a 39% six-month run, and analyst targets clustered at the current price — there is very little margin of safety if flows stall.
• Balance-sheet leverage: $13.3B of long-term debt against $11.7B of equity (D/E 1.42), part of which reflects consolidated investment products but which still limits flexibility in a downturn.
• Structural fee compression in traditional active management and the execution risk of swinging the mix toward alternatives (Stoneshield integration, private-market fundraising in a competitive market).

Franklin is executing a real turnaround — record $1.79T AUM in June and $1.83T in August 2026, $18.4B of quarterly long-term net inflows, revenue up 14.3% YoY, a 12.1–14.1% operating margin in the two quarters before last, and an alternatives build-out at ~65bps versus ~38bps firm-wide. But as of 2026-09-13 the stock has already run 39.5% in six months to $33.65, trades at a premium to its own five-year P/E and P/S averages, has analyst targets ($34.60 average) sitting essentially at the current price, and still reports ROIC of 1.4%, ROE of 4.3% and lumpy cash conversion. This is not a buy here: it is a fairly valued show-me story where the ~3.95% dividend pays you to wait for either a better entry or harder evidence that the earnings and cash-flow quality has genuinely normalized.

Applied a 13.0x justified forward P/E to my FY2027E adjusted EPS of $2.75 (a haircut to the Street's $2.892 to reflect recurring regulatory/integration charges and muted organic fee growth), giving $35.75. That multiple sits below BEN's five-year average trailing P/E of 16.0x — which is flattered by years of depressed earnings — and above the trough multiples of FY2023-24, and it implies a ~12x forward earnings yield on TTM revenue of $9.32B, ~$891M of TTM GAAP net income, Q3-FY26 adjusted EPS of $0.72 and a 3.95% dividend yield. Cross-check: at 12x the same EPS the stock is $33.00, at 14x it is $38.50, so $35.75 sits mid-range and modestly above both the $33.65 price and the $34.60 analyst consensus.